Abstract: A composition for treating chronic inflammation, including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D in synergistically effective amounts. A method of treating chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and treating chronic inflammation. A method of reducing and/or eliminating symptoms of chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and reducing and/or eliminating the individual's symptoms of chronic inflammation.

Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract: Disclosed are a liver specific delivery (LSD)-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof, and in particular, provided are a compound of formula (I), and an isomer, a pharmaceutically acceptable salt, a hydrate and a solvate thereof, and the corresponding pharmaceutical composition. The present invention also provides uses of the present compounds, alone or in combination with other antiviral drugs, in the treatment of the diseases caused by hepatitis B virus (HBV), hepatitis D virus (HDV) and human immunodeficiency virus (HIV).

Abstract: Disclosed are pharmaceutical compositions and methods of treating multiple myeloma by providing a pharmaceutically effective amount of each drug in a combination of drugs.

Abstract: The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, for treating cancer, or preventing cancer recurrence or progression; wherein ring A, Z1 and Z2 are as defined herein.

Abstract: An adhesive formulation is provided for use in a film wound dressing. The adhesive formulation includes a medical-grade adhesive and an antimicrobial substance. This adhesive formulation may be coated onto one or more surfaces of a medical-grade transparent film suitable for a wound dressing. The antimicrobial material may be a silane quaternary ammonium salt. The silane quaternary ammonium salt may comprise 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% of the silane quaternary ammonium salt. The medical-grade adhesive may comprise an acrylic adhesive. Further, the adhesive formulation may include about 0.01% to about 60% of the antimicrobial substance. The transparent film dressing may further include a release liner applied over the coated side(s) of the transparent film. The transparent film may comprise polyurethane.

Abstract: The present disclosure provides compositions and methods for treating and/preventing diseases and conditions associated with premature termination mutations. The methods disclosed herein comprise the step of administering to the subject a therapeutically effective dose of a compound described herein that induces read-through of the premature termination codon. The methods of the present disclosure may further comprise treating the subject with enzyme replacement therapy wherein the enzyme replacement therapy is selected for the disease or condition to be treated. Furthermore, the present disclosure provides method of pharmacologically suppressing premature termination codons in a subject in need of such suppression.

Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.

Abstract: This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures.

Abstract: Embodiments disclosed herein provide methods for treating neoplasm in a mammal, comprising intratumorally administering to the neoplasm an effective amount of a pharmaceutical composition comprising: a hapten; and a redox agent, whereby the neoplasm is treated.

Abstract: Novel treatment methods of controlling cell hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis or cardiac disorder are disclosed herein. Novel pharmaceutical compositions comprising adenosine or adenosine agonists and at least one selected from phytocannabinoids and terpenes are disclosed.

Abstract: Assays, methods and kits for predicting a subjects (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.

Abstract: Compositions are described that contain treated chitosan, modified chitosan and/or modified and treated chitosan for use in formulations for skin, hair and nails, and in compositions and methods of reducing topical agent-induced skin irritation and inflammation.

Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

Abstract: The present invention relates to an agent comprising anion-exchange groups that are suitable for adsorbing bacterial lipopolysaccharides (LPS) and/or lipoteichoic acids (LTA), for use in the prevention and/or treatment of inflammatory conditions and/or diseases of the oral cavity or in the vaginal region. The present invention also relates to a pharmaceutical composition that comprises an agent of this kind and can adhere to mucosa.

Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

Abstract: The present invention relates to an inhalation gas composition including oxygen and a mixture of inert gases, characterized in that said mixture of inert gases comprises a first compound selected from xenon and argon having hyperthermal properties, and a second compound having hypothermal properties, said mixture of inert gases comprising proportions of the first compound and of the second compound such that said mixture of inert gases is hypothermal.

Abstract: The invention discloses means of utilizing Noble Gases for inhibition of pathogenic processes associated with Alzheimer's Disease progression, as well as reversal of Alzheimer's Disease. In one embodiment compositions containing xenon gas are administered alone or together with therapeutic interventions for treatment of Alzheimer's Disease. In another embodiment, taupathies such as chronic traumatic encephalopathy are treated by administration of xenon or Noble Gas containing mixtures.

Abstract: The invention relates to compositions containing selenite-containing compounds and pharmaceutically acceptable acids, selected from citric acid, acetic acid, malic acid, carbonic acid, sulphuric acid, nitric acid, hydrochloric acid, fruit acids or mixtures thereof, for use for treating cervical inflammations, dysplasia and/or carcinomas. The invention further relates to methods of using such compositions.

Abstract: In various aspects, the present disclosure provides methods for applying ablation therapy to a target tissue region within a patient, which methods include: (a) navigating a catheter to a target tissue region within the patient, the catheter including an elongate body having a proximal portion and a distal portion and a balloon structure positioned at the distal portion of the elongate body, which balloon structure may be permeable to a calcium-ion-containing solution that comprises one or more calcium salts; (b) positioning the balloon structure at the target tissue region; (c) delivering energy to the target tissue region; and (d) eluting the calcium-ion-containing solution from the balloon structure before, during, and/or after delivering the energy to the target tissue region. In various other aspects, the present disclosure provides apparatuses that can be used for performing such methods, among others.

Abstract: Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage.

Abstract: New methods for the promotion of general sexual hygiene in a subject is provided by taking advantage of the safety and antimicrobial strength of hypochlorous acid in the form of a composition used as a sexual skin cleanser. These methods include the elimination of contact-to-contact STDs in a subject before and after sexual contact, and cleansing of pre- and post-sexual activity transmitted microorganisms.

Abstract: The invention concerns a mixture or a composition, that is preferably therapeutically active by topical administration, comprising: —at least one metal salt, the metal being chosen from molybdenum (Mo), tungsten (W), vanadium (V), gold (Au), a lanthanide, in particular lanthanum; —at least one chelating agent; —at least one source of peroxidative radicals; —at least one buffer agent; and pharmaceutical compositions constituted by or comprising said mixture, the methods for producing same and applications thereof, in particular in a method for the therapeutic treatment of a viral infection, and in particular involving a virus of the Herpesviridae family; or as an anti-inflammatory.

Abstract: The present invention relates to a pharmaceutical composition comprising granules which include an inert core coated with ferric citrate. The present invention also provides methods of manufacture thereof and methods of use thereof.

Abstract: Compositions contain an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to promote a swallowing reflex. The composition containing the combination of cinnamaldehyde and zinc can be used in a method to treat dysphagia and/or prevent aspiration pneumonia from dysphagia. In an embodiment, the composition containing cinnamaldehyde is administered to a human. The composition containing cinnamaldehyde may be a medicament, a food product or a supplement to a food product.

Abstract: A new composition and method for providing ophthalmic stem cell therapy is provided whereby a composition of sodium bicarbonate and stem cells in a 1:1 ratio is administered as an eye drop to a patient and results in measured visual acuity.

Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.

Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.

Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.

Abstract: The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.

Abstract: Described herein are methods of enriching and growing Type 2 innate lymphoid cells.

Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Abstract: Isolated cells of a mixed character, possessing a mesenchymal stem cell phenotype and a muscle cell phenotype, as well as extracellular vesicles secreted from same, pharmaceutical compositions comprising same, and methods of treatment comprising administering same, are provided. Further, methods of increasing engraftment of foreign cells by co-administering same are provided.

Abstract: Herein described is a method for treating cancer in a subject by administering a human umbilical cord perivascular cell (HUCPVC) that has been genetically modified to increase the expression of an oligonucleotide or a polypeptide such as an anti-cancer antibody.

Abstract: The present invention provides a highly-safe agent for regulating the intestinal microbiota distribution ratio. The agent of the present invention contains at least one of a Rhodobacter azotoformans BP0899 strain (Accession No. NITE BP-644) or a culture thereof.

Abstract: The present invention aims to provide an antimicrobial and antiviral agent which comprises a naturally occurring component as an active ingredient and is effective against microbes including various classes of fungi and viruses. In one aspect of the present invention, provided is an antimicrobial and antiviral agent comprising Lactobacillus derived from Artemisia indica var. maximowiczii.

Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate-degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.

Abstract: The invention provides for methods for treating and preventing colorectal cancer, non-dysplastic serrated polyps, or serrated crypt foci in a subject by administering butyrate producing bacteria, dietary fiber, sodium butyrate, or a combination thereof. The invention also provides methods for detecting, determining and/or diagnosing colorectal cancer, non-dysplastic serrated polyps, or serrated crypt foci in a subject by detection of the level of butyrate producing bacteria in a sample, as well as the alpha diversity, the operational taxonomic units, the level of bacteria Lactobacillales, and the level of CoA and BcoA nucleic acid.

Abstract: Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The subject in need thereof can have a gut microbiota signature characteristic of an adult. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiomtaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.

Abstract: The present invention relates to methods of treating gastrointestinal irregularity, as well as promoting, maintaining, and restoring gastrointestinal regularity, and maintaining healthy gut microflora in an individual. The present invention relates to methods comprising orally administering to an individual a Bacillus subtilis composition wherein the individual's gastrointestinal irregularity is treated, and/or the individual's gastrointestinal regularity and/or healthy gut microflora is promoted, maintained, and/or restored.

Abstract: The present invention relates to methods of improving body composition and reducing body fat percentage in an individual. The present invention relates to methods comprising administering to an individual a Bacillus subtilis composition wherein the individual's body fat percentage is reduced.

Abstract: Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiomtaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.

Abstract: The present disclosure belongs to the field of health care products, disclosing a powder formulation made from inulin, Auricularia, PORTA, LYCII FRUCTUS, MORI FRUCTUS, LONGAN ARILLUS, soy peptide powder, COICIS SEMEN, NELUMBINIS SEMEN and JUJUBAE FRUCTUS. The starting materials of the powder formulation are all from natural Chinese herbal medicine without addition of excipient. In addition, dose required for the powder formulation is small; it is easy to be taken and can be dissolved in water; it is soluble in cold water and can be absorbed quickly. The method for preparing the powder formulation in the present disclosure is simple and suitable for large-scale production. The powder formulation obtained has a good stability, long storage time, good taste. Experiments show that the powder formulation of the present disclosure can significantly enhance immunity, therefore can be used to prepare the health care foods having function on improving immunity.

Abstract: The present invention provides an aqueous extract of Andrographis paniculata leaves containing as main components andrographolide, neoandrographolide and 14-deoxy-11,12-didehydroandrographolide. The Invention also provides a method of production of said extract, comprising the steps of drying the leaves of Andrographis paniculata, and extracting them with water at a temperature of at least 50° C. The aqueous extract of Andrographis paniculata Leaves Is suitable for use as cognition enhancing agent having antineuroinflammatory and antioxidative effects.

Abstract: The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

Abstract: Herbo-mineral formulation for prevention, treatment and management of Diabetes and method of preparing the same are disclosed herein. The disclosed herbo-mineral formulation includes herb and mineral elements which facilitate in treating Diabetes and Diabetes associated complications. Further the disclosed formulation has been observed to exhibit hypoglycemic, hypolipidemic, and pancreatic cell regenerative properties.

Abstract: The present invention relates to a novel composition capable of enhancing tannins' ability to adhere to mucous membranes (mucosas) and skin, its use as a therapeutic composition, and products consisting of or comprising said composition.